Psychiatry and mental retardation: towards a behavioural pharmacological concept.

The authors wrote a think-piece, not an experiment. They looked at how doctors give mental-health labels to people with intellectual disability.

They said the labels miss the real picture. They urged teams to look at brain-behavior links before picking a drug.

The paper has no numbers. Its core claim: DSM tags like “depression” or “psychosis” fit poorly when the person also has ID.

The writers want a new map. Tie diagnosis to clear behavior-biology paths, not just symptom lists.

Matson et al. (1999) hunted for RCT proof on antipsychotics in ID-plus-schizophrenia and found none. That empty shelf backs the target paper’s warning: we lack drug guidance because our labels are weak.

Luckasson et al. (2013) and Matson et al. (2013) pick up the baton twenty years later. They give fresh naming rules and support-planning steps, turning the 1993 complaint into a concrete checklist you can use today.

Hall et al. (2007) shows the field did ditch the term “mental retardation,” just as the target hinted. The language moved on; now the diagnostic logic needs to catch up.

When a client with ID shows new self-hit, ask “What brain event triggers this?” before you write “bipolar.” Test functional relations first. Share that data with the prescriber. You will cut trial-and-error med changes and give the person quicker relief.